Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab - Wikidata - wikimedia - TriplyDB

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

http://www.wikidata.org/entity/Q42139247

about

Do nutritional supplements have a role in age macular degeneration prevention?Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review Ocular Complications of Diabetes and Therapeutic Approaches Updates on the Clinical Trials in Diabetic Macular Edema Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration The clinical utility of aflibercept for diabetic macular edema Age-Related Macular Degeneration: Advances in Management and Diagnosis Anti-angiogenic agents in metastatic colorectal cancer Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy Receptor tyrosine kinase-mediated angiogenesis Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept Targeted deletion of Vegfa in adult mice induces vision loss The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data.Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab.Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye.Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.Opioids: Modulators of angiogenesis in wound healing and cancer.A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interi Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Effect of intravitreal injection of ranibizumab on retinal ganglion cells and microvessels in the early stage of diabetic retinopathy in rats with streptozotocin-induced diabetes Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration.Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients.Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60.Aflibercept for the treatment of age-related macular degeneration.Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).Genetics of age-related macular degeneration: application to drug design Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys Choosing preclinical study models of diabetic retinopathy: key problems for consideration Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept.

P2860

Q21284507-D90B7C8D-2E1B-4F39-A63B-5655F25CF4D8 Q26744068-863DA433-AC5E-4236-A061-F84985CE4A17 Q26749412-F1F95C71-C598-4699-9422-911982F4F456 Q26767100-100D38A5-CC50-41F5-A96C-4AB4A74A3059 Q26771522-E4F6AAA9-5E5E-46FA-B6EC-164A2E096EE6 Q26783575-F0E74D28-F878-4D56-8D1F-9FACCBB2CCFF Q26799617-35B3321C-8B0E-4F86-A5DA-57CFB4A9F54E Q26801911-51F45992-CCAB-4F4E-8D72-EDC65EEA0BF1 Q26822421-BBE71B0E-9C94-4D26-8B7E-A6C729299272 Q26853604-8546648C-3BD4-4AB6-9162-596F6E418DEC Q27001612-BD5C261B-99EE-472A-8A8E-4FF8D1CE29FF Q28075557-3CFF0670-A5E8-402B-A422-49748A5E8D99 Q28513588-8E32E717-B74E-43DD-8F7C-55A9A869B70D Q28550616-8B8C4922-1979-4DBF-9866-721B858C96B5 Q30244247-7CE3D5AD-7ED6-4AD7-9E80-D4EE9AD5DED8 Q30490267-1FD75DC2-6797-4B26-AD76-0FA5C4528870 Q30490563-D6C2137D-2F55-411B-84ED-C0A526563CD3 Q30490738-E76A494E-E6DA-4C8F-832D-A73A57875099 Q30948835-51F67A40-82FF-453C-8F1C-52013DBBF980 Q33596886-0B4E7743-AA5F-4B92-A5C5-F90A7EFF22B7 Q33623357-BF73147A-F7C3-4CF0-88CE-471689DF774B Q33624977-EB2D1321-39C1-4E38-922D-5811A576C162 Q33649031-9588DCE1-30D9-46E9-A232-A54E6B9B1388 Q33659405-CDCB6D5F-3231-4036-A98C-EEFEC104CA3C Q33722777-DD0C4C13-E090-49CF-937A-89218AA326DB Q33740152-80A9C7D6-8954-4706-BC91-8E4C2B2D08B7 Q33744652-980EB3D0-1B2F-443F-BBC6-4BFEF76E5648 Q33790460-11365610-B9CA-480B-B959-2C7D0F87AAF4 Q33829621-4731CAF2-2DBB-428A-9D8C-B0C3CE03B765 Q33858304-AE9DAB06-5B02-4D5A-8D81-571853D777CB Q33939215-A1BC885C-6365-4422-9690-37FBC81996EC Q33995887-0474C4E2-81E9-4492-B295-A77F0182F24A Q34092454-EE5E74AC-E9CA-4498-B21B-E05EBB8ED19F Q34103580-F6591BD3-A3AF-4B08-BD8A-E99A7AC1C97A Q34253393-F2D57577-0066-4CE9-8716-A072D2C46EC5 Q34557530-D3B211B5-F08A-4CFD-B255-0E617E506875 Q34564352-270C627C-7A35-4B90-B3F5-CD2FB4703A3C Q34608306-CC7F8005-02A3-485B-B546-891F1AE8A467 Q34624487-89045DFC-8225-464A-944C-52B4AD7BE983 Q34642583-A27EF83E-BC39-4A93-AE02-E32669C46234

P2860

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

http://www.wikidata.org/entity/Q42139247

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Binding and neutralization of ...... p, ranibizumab and bevacizumab

@en

Binding and neutralization of ...... p, ranibizumab and bevacizumab

@nl

type

label

Binding and neutralization of ...... p, ranibizumab and bevacizumab

@en

Binding and neutralization of ...... p, ranibizumab and bevacizumab

@nl

prefLabel

Binding and neutralization of ...... p, ranibizumab and bevacizumab

@en

Binding and neutralization of ...... p, ranibizumab and bevacizumab

@nl

P1433

Q42139247-E8F877C3-A109-43DD-89E5-CEDC52709289

P1476

Q42139247-56BA1541-9367-43E1-A967-0C423FCDBC13

P2093

Q42139247-37D4FDE3-9965-401D-917A-8C6637618E40

Q42139247-4FD7FD41-7B32-4E90-AE13-407311AF8763

Q42139247-67E8895A-78A4-495B-9DD0-6EE58D4B7950

Q42139247-7F79171A-AFD0-47E7-B250-115790EDF816

Q42139247-8D2D4B53-B1F6-491E-BDBF-C2AF5B3077B2

Q42139247-8F4AB7C4-F17B-4124-8D06-9F437BEB5F75

Q42139247-97B6B546-2236-4612-A479-111BA6B96A6E

Q42139247-9F5B748A-7C1A-4CCF-8F01-419F2AC6E9E1

Q42139247-A699165D-3448-4A7C-BAA7-4059B1D2B16F

Q42139247-ECF354E4-77BF-46D5-BEF2-F78977F26AFB

P2860

Q42139247-02EE3310-27E5-4540-919A-CF568AE4B2C7

Q42139247-077EB06A-5433-4158-B40B-9B3349223FD4

Q42139247-121EB926-9581-493E-A546-072E4DE01E54

Q42139247-1460E725-30BE-4F5B-A09F-3056F35BCB69

Q42139247-158D29CB-F661-49E3-A48E-D31AF1063CE5

Q42139247-1C373D7C-9D23-427E-BBED-8CB04FE90B46

Q42139247-1CEA0087-BF91-44BB-9BE3-E6EFDBFC87B7

Q42139247-1F2C1253-7A32-43FD-AE00-CA3325E194B8

Q42139247-205711B3-FFE0-4698-8DAE-05E01C76AEA6

Q42139247-24387125-4409-403E-AB59-B6B9D13065C1

P2888

Q42139247-F6534CE7-21BF-4EB1-8A08-1E5963E7BC33

P304

Q42139247-19EE0607-7533-418D-930E-2E0E2C97717D

P31

Q42139247-0F84CEDA-9EAA-46D4-9C1F-7049390C5401

P356

Q42139247-60231E6B-6E99-4C67-A832-2A26C73DBCC7

P433

Q42139247-5C7ACC07-3EDA-4858-9E99-10A49B2CF7F8

P478

Q42139247-7EC97628-5039-45CC-B909-DA5CF77A49E6

P577

Q42139247-F78C8217-558E-4A40-8D00-ED6BAFC37A8D

P5875

Q42139247-D0747F1E-18A2-44C5-8FFB-7E60E337EF59

P6179

Q42139247-5D92231E-B640-49A8-980D-666DDCA2477C

P698

Q42139247-BCC0AE58-C81B-4E3F-8563-19F5B448C89D

P921

Q42139247-45673B5D-1D3E-4792-8A7F-786603AEDA1F

Q42139247-D81CD01C-6D83-4CD3-9B82-9A8B96B6ED31

P932

Q42139247-E44A28DE-2D4D-4438-9AA0-4E053A8C753F

P356

S10456-011-9249-6

P1433

P1476

Binding and neutralization of ...... p, ranibizumab and bevacizumab

@en

P2093

Ashique Rafique

http://www.w3.org/2001/XMLSchema#string

Ergang Shi

http://www.w3.org/2001/XMLSchema#string

Erica A Pyles

http://www.w3.org/2001/XMLSchema#string

George D Yancopoulos

http://www.w3.org/2001/XMLSchema#string

Joel Martin

http://www.w3.org/2001/XMLSchema#string

Michael P Rosconi

http://www.w3.org/2001/XMLSchema#string

Neil Stahl

http://www.w3.org/2001/XMLSchema#string

Nicholas Papadopoulos

http://www.w3.org/2001/XMLSchema#string

Qin Ruan

http://www.w3.org/2001/XMLSchema#string

Stanley J Wiegand

http://www.w3.org/2001/XMLSchema#string

P2860

Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

The biology of VEGF and its receptors

Angiogenesis in cancer and other diseases

Cytokine traps: multi-component, high-affinity blockers of cytokine action

A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium

P2888

s10456-011-9249-6

P304

171-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10456-011-9249-6

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221803111

http://www.w3.org/2001/XMLSchema#string

P6179

1021493027

http://www.w3.org/2001/XMLSchema#string

P698

22302382

http://www.w3.org/2001/XMLSchema#string

P921

P932

3338918

http://www.w3.org/2001/XMLSchema#string